Daniel Hawkins learned medical technology before he learned the phrase medical technology. In West Philadelphia, his father’s primary-care practice occupied the first floor of the family home. The rooms upstairs were domestic; downstairs, medicine was also a small business. Hawkins and his siblings checked coding on public-assistance forms. Patients, paperwork, service and solvency arrived through the same front door. The arrangement gave him an early view of a truth that would organize his career: a good clinical idea still has to survive contact with a workflow.
He had his own small enterprises. Around Christmas he sold clippings from a holly tree door to door. Later, he operated soda machines to help pay his way through Wharton. He liked science and once imagined pursuing pre-med and business simultaneously, until the deans suggested he reconsider the workload. Business won, but medicine never really lost. After graduating in 1989, Hawkins worked in leveraged buyouts in Manhattan. He quickly decided that he preferred the entrepreneur’s side of the table, returned west for an MBA at Stanford, and went looking for a way to combine enterprise with clinical work at scale.
The workflow is part of the machine
At Intuitive Surgical, Hawkins was an early non-technical hire and built the marketing function around the emerging da Vinci robot. “Marketing” in a category that did not yet exist meant something more physical than campaigns. It meant helping decide what the product had to do, translating between clinicians and engineers, and watching whether a procedure could be made repeatable.
One assignment took him to Dresden, Germany, where he sold Intuitive’s first robot. The clinical team was trying to perform closed-chest cardiac bypass. A procedure had taken roughly 12 hours. Hawkins has recalled that his deal with then-CEO Lonnie Smith was blunt: live in Dresden until the group could complete the workflow in 45 minutes. He stayed about a month. The target was reached. The machine mattered, but so did every movement, handoff and decision surrounding it.
That became a recurring pattern. Hawkins would enter where a powerful technology met an awkward operating reality. At Calibra Medical, which Johnson & Johnson acquired, he and his collaborators worked on a wearable insulin-delivery patch. At Shockwave Medical, founded with John Adams and Todd Brinton, the problem was calcified plaque inside blood vessels. The team combined the familiar mechanics of an angioplasty balloon with pressure waves derived from lithotripsy. Hawkins served as inventor, program manager, marketer and founding CEO as the idea moved from prototype through testing, regulatory work and early commercial use.
The concept did not glide through venture capital. Hawkins has said roughly 50 investors turned it down. The timing, during the financial crisis, did not help. Neither did the unfamiliar category. But his favorite question was never whether an idea sounded impressive. It was: “Does your product have natural pull?” Shockwave’s system eventually found that pull, established intravascular lithotripsy as a category, went public after Hawkins handed leadership to a successor, and was acquired by Johnson & Johnson for $13.1 billion in 2024.
The one-button instinct
Hawkins is not an engineer by training. He calls himself technically minded, and his account of invention is notably social. He reads physiology, learns enough of the engineering principles to frame questions, then brings those questions to people who can go deeper. Expertise is something to coordinate, not impersonate. His role is often translation: the clinical need into a product requirement, the engineering capability into a usable motion, and the usable motion into a business someone can adopt.
Simplicity is the other half of the method. In a recent discussion of Shockwave’s commercialization, Hawkins described an early goal: make the system incredibly easy to use and nearly impossible to misuse. Physicians asked for more dials and controls. The team resisted. More settings meant more variability, and variability could alter outcomes. A one-button deployment placed the complexity inside the system rather than on the operator’s fingertips.
Avail Medsystems tested the same instinct in a different form. After traveling about a quarter-million miles for Shockwave in 2016, Hawkins stepped away in 2017, spent more time with family, and developed the idea for an operating-room telepresence network. Medical-device experts often traveled in person to support procedures. Avail built a hardware-and-software system intended to make remote collaboration dependable and consistent from room to room. Hawkins even chose a name with two meanings: expertise could be always available, and a team could avail itself of that expertise.
The company raised more than $100 million and placed hundreds of systems, but shut down in 2023 when financing disappeared; its technology went to medical-robotics company Mendaera. Hawkins speaks plainly about the end. The market had been created, but the capital environment took the company out of the game. It is an important complication in a career that includes large exits. A needed product, a working system and substantial funding can coexist with failure. Market creation has no immunity from timing.
The overlooked half of imaging AI
Vista AI brought Hawkins back to a familiar kind of constraint. Much of imaging AI works after a scan, helping analyze what the machine has already captured. Vista works during acquisition. Its software controls existing MRI machines, automating steps such as localization and scan planning while processing information in real time. Hawkins’s pitch is operational: advanced exams should be faster and more consistent, and less dependent on finding a scarce specialist for every location.
The company’s first commercial platform focuses on cardiac MRI. Its ambition is broader: automated acquisition across brain, prostate, spine and other anatomies, subject to FDA clearance. In January 2026, Vista announced a $29.5 million Series B led by an unusual mix of venture investors and health systems, including Cedars-Sinai, Intermountain Health, University of Utah Hospital System, Temple University/Fox Chase Cancer Center and Tampa General Hospital. Hospital investors do more than validate a slide deck. They place the buyer close to the design table.
At Brigham and Women’s Hospital, Vista reports that its software enabled 50 percent more cardiac MRI slots and eliminated a 28-day backlog without adding staff, scanners or operating hours. At Radiology Regional in Florida, the company says scan times fell by more than half while technologists without prior cardiac MRI experience reliably completed exams. These are company-reported results, but they illustrate the unit Hawkins cares about: not abstract intelligence, but usable capacity.
A career built around the constraint
Hawkins’s companies can look unrelated when arranged by object: a robot, a catheter, a telepresence cart, a software layer for a magnet. Arrange them by constraint and the line becomes clear. A robot needed a viable procedure. A vascular invention needed fewer controls and a new clinical category. A remote platform needed the same dependable experience in every operating room. MRI needs complex acquisition to become more consistent, less dependent on geography and easier to fit into the day.
This is why “market creation” is more specific than it first sounds. It is not a euphemism for persuading people to want something. It is the work of designing the whole adoption path: who uses the product, what they stop doing, what can go wrong, how the economics hold, and whether the result is repeatable on an ordinary Tuesday. The market begins inside those details.
Hawkins has said that his five-year aim is to see Vista on 75 to 80 percent of MRI magnets in the United States. It is an aggressive target, dependent on product development, regulatory clearances and hospital adoption. Yet the more revealing aspiration is architectural. He wants sophisticated imaging capability to travel as software across machines hospitals already own. The scanner stays. The doorway around it gets wider.
There is a child’s question inside that plan: why must a difficult thing remain difficult? The adult knowledge lies in everything Hawkins has learned about capital, regulation, procedure design and the stubbornness of institutions. His career sits at their intersection, where imagination is useful only when it can be translated into a button someone trusts, a workflow a team can repeat and a market sturdy enough to last.